Great pickup. The US market for ARDS was estimated to be +$800 million to $1 billion prior to COVID so the market opportunity with these increased cases is massive.
Incidentally there is a huge economic impact from ARDS that is not often discussed which concerns unemployment or under-employment. We know the mortality rate for ARDS patients is very high but the statistics I’ve read for survivors is also sobering. Many survivors are unable to return to work for 12-24 months due to the impact of ARDS on the body. This economic burden becomes an added expense to the social system.
The point is any genuine drug for ARDS has a really chance of receiving public subsidies, such as the PBS or equivalent.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-2337
-
-
- There are more pages in this discussion • 17,659 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)